Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia

被引：0
|
作者：
Wang, Lijun [1 ]
Chen, Yu [2 ]
Wang, Qingyuan [1 ]
Xiang, Meng [1 ]
Zeng, Zhao [1 ]
Zhang, Zhibo [1 ]
Zhang, Fenghong [1 ]
Chen, Suning [1 ,3 ,4 ]
Xue, Mengxing [1 ,4 ]
机构：
[1] Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Wannan Med Coll, Dept Hematol, Affiliated Hosp 2, Wuhu, Peoples R China
[3] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[4] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suning Chen & Mengxing Xue, Shizi St 188, Suzhou 215006, Peoples R China
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2024年 / 46卷 / 03期
基金：
中国国家自然科学基金;
关键词：
PAX5; TRANSFORMATION; GENE;
D O I：
10.1111/ijlh.14245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：571 / 574
页数：4
相关论文
共 50 条
  • [31] Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
    Naoto Takahashi
    Masatomo Miura
    Stuart A Scott
    Hideaki Kagaya
    Yoshihiro Kameoka
    Hiroyuki Tagawa
    Hirobumi Saitoh
    Naohito Fujishima
    Tomoko Yoshioka
    Makoto Hirokawa
    Kenichi Sawada
    Journal of Human Genetics, 2010, 55 : 731 - 737
  • [32] Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
    Takahashi, Naoto
    Miura, Masatomo
    Scott, Stuart A.
    Kagaya, Hideaki
    Kameoka, Yoshihiro
    Tagawa, Hiroyuki
    Saitoh, Hirobumi
    Fujishima, Naohito
    Yoshioka, Tomoko
    Hirokawa, Makoto
    Sawada, Kenichi
    JOURNAL OF HUMAN GENETICS, 2010, 55 (11) : 731 - 737
  • [33] Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia
    Fazio, Grazia
    Bresolin, Silvia
    Saitta, Claudia
    Silvestri, Daniela
    Vendramini, Elena
    Palmi, Chiara
    Rigamonti, Silvia
    Galbiati, Marta
    Quadri, Manuel
    Mecca, Stefano
    Savino, Angela Maria
    Bardini, Michela
    Grioni, Andrea
    Valsecchi, Maria Grazia
    te Kronnie, Geertruy
    Biondi, Andrea
    Cazzaniga, Giovanni
    BLOOD, 2019, 134
  • [34] CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE
    Jawharl, M.
    Naumann, N.
    Schwaab, J.
    Dietz, C.
    Casper, J.
    Dang, T. A.
    Dietze, L.
    Doehner, K.
    Haenel, A.
    Lathan, B.
    Link, H.
    Lotfti, S.
    Mielkel, S.
    Luber, V.
    Maywald, O.
    Mueller, L.
    Platzbecker, U.
    Pruemmer, O.
    Thomssen, H.
    Toepelt, K.
    Schmitt, K.
    Baurmann, H.
    Vielert, T.
    Hofmann, W. K.
    Haferlach, C.
    Cross, N. C.
    Fabarius, A.
    Reiter, A.
    Metzgeroth, G.
    HAEMATOLOGICA, 2016, 101 : 264 - 265
  • [35] Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
    Guilhot, Joelle
    Baccarani, Michele
    Clark, Richard E.
    Cervantes, Francisco
    Guilhot, Francois
    Hochhaus, Andreas
    Kulikov, Sergei
    Mayer, Jiri
    Petzer, Andreas L.
    Rosti, Gianantonio
    Rousselot, Philippe
    Saglio, Giuseppe
    Saussele, Susanne
    Simonsson, Bengt
    Steegmann, Juan-Luis
    Zaritskey, Andrey
    Hehlmann, Ruediger
    BLOOD, 2012, 119 (25) : 5963 - 5971
  • [36] The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate
    Lee, Sung-Eun
    Choi, Soo Young
    Bang, Ju-Hee
    Kim, Soo-Hyun
    Jang, Eun-jung
    Byeun, Ji-Young
    Park, Jin Eok
    Jeon, Hye-Rim
    Oh, Yun Jeong
    Kim, Myungshin
    Kim, Dong-Wook
    CANCER GENETICS, 2012, 205 (11) : 563 - 571
  • [37] PHASE 2 CLINICAL-TRIAL WITH VINDESINE FOR REMISSION INDUCTION IN ACUTE-LEUKEMIA, BLASTIC CRISIS OF CHRONIC MYELOID-LEUKEMIA, LYMPHOSARCOMA AND HODGKINS-DISEASE - ABSENCE OF CROSS RESISTANCE WITH VINCRISTINE
    MISSET, JL
    DEVASSAL, F
    HAYAT, M
    MACHOVER, D
    BELPOMME, D
    SCHWARZENBERG, L
    RIBAUD, P
    MUSSET, M
    JASMIN, C
    MATHE, G
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1977, 3 : S21 - S21
  • [38] Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
    Frankel, Arthur
    Liu, Jen-Sing
    Rizzieri, David
    Hogge, Donna
    LEUKEMIA & LYMPHOMA, 2008, 49 (03) : 543 - 553
  • [39] Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial
    Kwak, Jae-Yong
    Kim, Hawk
    Kim, Jeong A.
    Do, Young Rok
    Kim, Hyeoung Joon
    Park, Joon Seong
    Chung, Joo Seop
    Shin, Ho-Jin
    Kim, Sung-Hyun
    Kim, Dae-Young
    Bunworasate, Udomsak
    Choi, Chul Won
    Comia, Narcisa Sonia Cornejo
    Zang, Dae Young
    Oh, Sukjoong
    Jootar, Saengsuree
    Reksodiputro, Ary Harryanto
    Lee, Won Sik
    Mun, Yeung-Chul
    Kong, Jee Hyun
    Caguioa, Priscilla B.
    Park, Jinny
    Jung, Chul Won
    Kim, Dong-Wook
    BLOOD, 2015, 126 (23)
  • [40] Influence of CYP3A5 and SLCO1 on Imatinib Response Among Egyptian Patients with Chronic Myeloid Leukemia in Chronic Phase
    El Baiomy, Mohamed Ali, Sr.
    Aref, Salah
    El-Ghonemy, Mohamed
    BLOOD, 2016, 128 (22)
12345